お知らせ • Jun 30
Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025 Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025. お知らせ • May 28
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in funding Rapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing. お知らせ • May 27
Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery Technology Rapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters. お知らせ • Feb 19
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in funding Rapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing. お知らせ • Dec 11
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding Rapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share. お知らせ • Oct 31
Rapid Dose Therapeutics Corp. announced that it has received CAD 0.851 million in funding On October 30, 2024. the company has closed the final tranche of the transaction お知らせ • Jun 27
Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024 Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024. お知らせ • Mar 26
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding Rapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing. お知らせ • Jan 20
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in funding Rapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent. お知らせ • Sep 23
Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of Directors Rapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023. お知らせ • Jun 03
Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023 Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023. お知らせ • May 11
Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian Market Rapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia.